Wojewodzki Szpital Specjalistyczny W Bialej Podlaskiej — Clinical Trial Site

35 Registered trials

19 Currently recruiting

Organisation

Wojewodzki Szpital Specjalistyczny W Bialej Podlaskiej

Location

Biala Podlaska, Poland

Identifier

ORG-100047025

Address

Ul. Terebelska 57/65, 21-500, Poland

Departments

651: Oddzial Onkologii Klinicznej
Department of Clinical Oncology
Hematology
N/A
NA
Oddzial Chemioterapii Dziennej
Oddzial Onkologii Klinicznej
Oddział Hematologii
Oddział Onkologii Klinicznej
Oddział Onkologii Klnicznej
Osrodek Innowacyjnych Terapii
PL30005:Osrodek Innowacyjnych Terapii

Clinical trials at this site (35)

Search interface

Studies testing Ziftomenib together with standard treatments in adults with newly diagnosed acute myeloid leukemia (AML) that has specific g… Recruiting

2025-521314-25-00 NPM1-m and KMT2A-r Acute Myeloid Leukemia 5 2026-03-19
A Multicenter, Open-Label, Dose-Finding, Phase 2 Study Evaluating THIO Sequenced with Cemiplimab (LIBTAYO®) in Subjects with Advanced Non-Sm… Recruiting

2023-504595-26-00 Non-Small Cell Lung Cancer 4 2023-05-22
A Phase Ib/II Study of APG-2575 as a Single Agent or in Combination with Other Therapeutic Agents in Patients with Relapsed and/or Refractor… Recruiting

2024-515654-25-00 Relapsed and/or Refractory Chronic Lymphocytic Leukemia 9 2021-12-20
Study of Izalontamab Brengitecan (BMS-986507) versus Treatment of Physician’s Choice in Patients with Previously Untreated, Locally Advanced… Recruiting

2024-519871-24-00 Breast cancer 10 2025-11-11
A research study comparing CDR132L with placebo on the structure and function of the heart in people with heart failure with reduced/mildly … Recruiting

2024-515797-27-00 Heart Failure with Reduced/Mildly Reducede Ejection Fra 4 2025-06-25
A trial to learn how well saruparib with camizestrant works and how safe it is in adults with advanced breast cancer that is hormone recepto… Recruiting

2023-504180-16-00 Advanced Breast Cancer 5 2025-04-07
Amivantamab + FOLFIRI Versus Cetuximab/Bevacizumab + FOLFIRI in Participants With Recurrent KRAS/NRAS and BRAF Wild-type Colorectal Cancer Recruiting

2024-513853-66-00 KRAS/NRAS and BRAF Wildtype Recurrent, Unresectable or 5 2025-02-04
Amivantamab + Chemotherapy Versus Cetuximab + Chemotherapy in Treatment-naïve Participants with KRAS/NRAS and BRAF Wild-type Colorectal Canc… Recruiting

2024-513852-13-00 KRAS/NRAS and BRAF Wild-type Unresectable or Metastatic 5 2025-01-20
A Phase 3, randomized, open-label, multicenter, controlled study to evaluate the efficacy and safety of zanidatamab in combination with phys… Recruiting

2023-508960-31-00 Metastatic HER2-positive breast cancer 5 2024-12-03
Study of MEN1703 in Patients with Relapsed or Refractory Aggressive B-cell Non-Hodgkin Lymphoma Recruiting

2024-513098-31-00 Relapsed or Refractory Aggressive B-cell Non-Hodgkin Ly 4 2024-11-14
Clinical trial testing an investigational drug RVU120 for myelofibrosis (myeloproliferative neoplasm, MPN) Recruiting

2024-511688-27-00 Myelofibrosis 4 2024-09-19
Phase III study to evaluate the effect of balcinrenone/dapagliflozin in patients with heart failure and impaired kidney function Recruiting

2023-508162-15-00 Chronic HF and comorbid impairment of kidney function w 5 2024-07-12
Multi-cohort Study to Customize Ibrutinib Treatment Regimens for Patients with Previously Untreated Chronic Lymphocytic Leukemia TAILOR Recruiting

2023-504044-34-00 Untreated Chronic Lymphocytic Leukemia 4 2024-04-17
An Adjuvant Endocrine-based Therapy Study of Camizestrant (AZD9833) in ER+/HER2- Early Breast Cancer (CAMBRIA-2) Recruiting

2023-504031-41-00 ER+/HER2- Early Breast Cancer 5 2024-03-25
Study Comparing the Efficacy and Safety of the Combination of Lasofoxifene and Abemaciclib to the Combination of Fulvestrant and Abemaciclib… Recruiting

2023-503708-10-00 Locally advanced or metastatic breast cancer 5 2024-02-20
A Multicenter, Open-Label, Dose-Finding Clinical Trial to Assess the Safety, Pharmacokinetics, Pharmacodynamics, and Clinical Efficacy of RV… Recruiting

2023-505911-19-00 Acute Myeloid Leukemia 4 2024-01-05
A Phase 3 Study Comparing Pirtobrutinib to Ibrutinib in CLL/SLL Recruiting

2023-507699-38-00 Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma 5 2022-08-30
PHASE I STUDY TO DETERMINE THE MAXIMUM TOLERATED DOSE FOR TRICHOSTATIN A IN SUBJECTS WITH RELAPSED OR REFRACTORY HEMATOLOGIC MALIGNANCIES Recruiting

2024-518454-17-00 relapsed/refractory hematologic malignancies 1 2021-01-08
Pan tumor Roll Over Study Recruiting

2023-506914-32-00 Pan tumor 4 2020-05-05
ARTEMIS - A research study to look at how ziltivekimab works compared to placebo in people who have had a heart attack Ended

2023-506876-28-00 The medical condition we are investigating is type 1 AM 5 2024-08-01
A Phase 1 Randomized, Open Label Pharmacokinetic Comparability Study Comparing Pre- and Post-change Teclistamab in Participants with Relapse… Ended

2023-508426-10-00 Relapsed/Refractory Multiple Myeloma 3 2024-06-03
A Phase 3 Randomized Study Comparing Talquetamab in Combination with Pomalidomide (Tal-P), Talquetamab in Combination with Teclistamab (Tal-… Ended

2022-502446-27-00 Relapsed or Refractory Myeloma 5 2024-02-26
LIBREXIA-AF A Phase 3 Active-controlled Study of Milvexian for Prevention of Cardioembolic Events in Participants with Atrial Fibrillation Ended

2022-501419-15-00 Atrial Fibrillation 5 2023-08-23
A Phase 3 Study Comparing Pirtobrutinib (LOXO-305) to Bendamustine plus Rituximab in Untreated Patients with CLL/SLL Ended

2024-511599-33-00 Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma 5 2021-12-22